DALLAS--(BUSINESS WIRE)--HemoBioTech (OTCBB: HMBT, www.hemobiotech.com) announced today that it received an exclusive worldwide license from Texas Tech University System for a new technology that addresses the safety of animal-derived products for human use in pharmaceutical, cosmetic and other industries. This new technology could prevent the spread of transmissible spongiform encephalopathies (“TSE”), also know as prions or mad cow disease, as well as viruses. The Food and Drug Administration (“FDA”) strictly regulates medicinal products and cosmetics that contain ingredients from animals, particularly of bovine origin. The technology is being used in the manufacturing of HemoBioTech’s lead product HemoTech, potentially the first viable substitute for human blood. HemoTech is composed of chemically modified bovine hemoglobin.
